All In Biotech

NDA 021229 · Astrazeneca

Prilosec Otc

Omeprazole Magnesium · Oral

Last checked: Nov 20, 2026Latest source record: Oct 4, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jun 20, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

988

158 Phase 3, 48 recruiting

FAERS reports

31,002

23,793 serious, 2,661 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 5, 2026.

Use treats frequent heartburn (occurs 2 or more days a week) not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • PRILOSEC OTC · OMEPRAZOLE MAGNESIUM EQ 20MG BASE · TABLET, DELAYED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.

All 988 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease18,104
  • acute kidney injury9,430
  • renal failure7,624
  • end stage renal disease5,802
  • renal injury5,352
  • tubulointerstitial nephritis2,343
  • hyperchlorhydria2,167
  • pain2,132
  • rebound effect2,006
  • gastrooesophageal reflux disease1,959
  • drug ineffective1,699
  • drug dependence1,679

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200437
200555
200665
200787
2008229
2009603
2010438
2011691
20121,229
2013623
2014570
2015683
2016634
2017538
20189,084
20198,419
20202,576
20211,906
2022660
2023373
2024390
2025582
2026530

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,390 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.